The World united on February 28th for Rare Disease Day, a global initiative dedicated to raising awareness for the approximately 300 million people living with rare diseases worldwide. A rare disease is generally defined in the US as affecting fewer than 200,000 people, and in the EU as affecting fewer than 5 in 10,000 people. Rare Disease Day is a powerful reminder of the daily challenges faced by patients, families, and caregivers and of the urgent need for collaboration to drive change. Worldwide, more than 10,000 rare diseases have been identified, many of which are genetic, chronic, and life-threatening. Despite the “rare” label, their collective impact is anything but small. Yet many lack adequate treatments, care, or support systems.

Observed in over 100 countries, Rare Disease Day brings together patient stories, educational campaigns, and policy forums to amplify a unifying message: while each rare disease affects relatively few individuals, together they represent a major global public health priority. This shared advocacy helps raise public understanding, influence policy decisions, and encourage research collaborations. These are all critical steps toward improving diagnosis, treatment, and quality of life for those living with rare diseases.

The US Food & Drug Administration (FDA) marked the start of Rare Disease Week with a virtual public meeting on Monday, February 23, 2026, themed “Moving Forward. Looking Ahead. An Event for Patients.” This patient-centered event underscored the agency’s commitment to deeper collaboration with patients and communities to accelerate the development of medical products for rare diseases. Key discussions focused on patient-focused FDA initiatives, patient engagement opportunities, the challenges and opportunities of AI technology in rare disease development, and the role of real-world data and real-world evidence. There was a clear message that the patient voice must inform every stage of medical product development and regulation. By focusing on patients, the FDA is ensuring that regulatory decisions reflect real-world needs and accelerate meaningful therapies.

FDA initiatives for rare diseases: The Plausible Mechanism Framework

Coinciding with the February 23 meeting, the FDA issued draft guidance on the Plausible Mechanism Framework for individualized therapies targeting ultra-rare genetic conditions. This new framework addresses one of the biggest barriers in rare disease drug development – the challenge of conducting traditional randomized controlled trials when patient populations are extremely small. The guidance “Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause” outlines a structured pathway for generating substantial evidence of safety and effectiveness through:

  • Precise identification of the disease-causing genetic, cellular, or molecular abnormality
  • Therapies that directly target the root cause or proximate biological pathway with a clear mechanistic rationale
  • Potential for reliance on well-characterized natural history data from untreated patients or baseline data from trial participants
  • Confirmation that the therapy successfully drugged and/or edited the target
  • Demonstration of meaningful clinical improvement

This flexible, science-driven approach allows data from limited numbers of patients while still meeting regulatory standards. The aim is to remove unnecessary barriers, encourage innovation in personalized medicine, drive down costs, and deliver life-saving options to patients who have waited far too long. It is clear that FDA is prioritizing regulatory flexibility paired with rigorous science to bring more therapies to patients faster.

Unlocking innovation: How regulatory expertise makes it happen

Developing treatments for rare diseases will always involve unique challenges such as small patient populations, complex trial designs, and high costs. But modern regulatory frameworks are designed to overcome them. In the US, the FDA’s Orphan Drug Designation offers powerful incentives such as tax credits for clinical testing, user fee exemptions, and seven years of market exclusivity upon approval. Similar programs exist through the European Medicines Agency (EMA) in the EU.

This is exactly where expert regulatory consulting becomes essential. At Lumanity, we specialize in helping pharmaceutical and biotech companies navigate these evolving pathways efficiently and strategically. Our services include:

  • Orphan drug applications: Expert guidance through the designation process to secure valuable incentives and streamline development
  • Clinical trial strategy: Designing adaptive, innovative trials that respect limited patient pools while robustly meeting regulatory expectations
  • Health authority interactions: End-to-end support for engagements with health authorities including meeting strategy, briefing package development, question management, and clear regulatory positioning
  • Regulatory strategy and submission support: Creating clear and integrated regulatory strategies from candidate selection through to Investigational New Drug (IND) filing to marketing approval with comprehensive preparation of INDs, lifecycle submissions, and New Drug Applications (NDAs)/Biologic License Applications (BLAs) enabling timely approvals and sustained compliance

By partnering with sponsors early and often, we help translate scientific promise into approved therapies that reach patients faster.

Partnering for progress on Rare Disease Day and beyond

Rare Disease Day reminds us that rare does not mean invisible and that collective action can transform lives. The FDA’s recent actions, from the patient-focused February 23 meeting to the Plausible Mechanism Framework, show real regulatory momentum. Now is the time for sponsors, researchers, and advocates to lean into these opportunities.

At Lumanity, we’re proud to support this cause by bridging the gap between cutting-edge innovation and successful regulatory approval. If you’re developing treatments for rare or ultra-rare diseases, whether planning an Orphan Drug application, designing trials for individualized therapies, or preparing submissions under the latest FDA guidance, our team is ready to help.

Contact us today to discuss how we can partner in advancing equitable, patient-centered healthcare solutions. Together, we can move forward, look ahead, and deliver the therapies patients need most.